$BIOCON reduced its net debt to EBITDA ratio by 1.6x through refinancing and EBITDA growth. The company restructured $1,389 million of debt into a new $1,348 million profile, deferring maturities to FY28-FY30. Biocon also increased its stake in Biocon Biologics to 99.2% and completed major capacity investments. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.